ResMed moves beyond sleep with trial of new heart failure ventilation therapy BRW (subscription) ResMed has made its name in the global $US8 billion sleep therapy market but if a new trial proves successful the company could become a player in the treatment of heart failure, a condition that costs the US government alone $US35 billion each year. |
